Canagliflozin Facilitates Reverse Cholesterol Transport Through Activation of AMPK/ABC Transporter Pathway

References

• LuoJ, YangH, SongBL. Mechanisms and regulation of cholesterol homeostasis. Nat Rev Mol Cell Biol. 2020;21:225–245.31848472
   PubMed Web of Science ®Google Scholar
• WangHH, GarrutiG, LiuM, et al. Cholesterol and lipoprotein metabolism and atherosclerosis: recent advances in reverse cholesterol transport. Ann Hepatol. 2017;16:s27–s42. doi:10.5604/01.3001.0010.5495
   PubMed Web of Science ®Google Scholar
• BerbéeJ, BoonM, KhedoeP, et al. Brown fat activation reduces hypercholesterolaemia and protects from atherosclerosis development. Nat Commun. 2015;6(1):6356. doi:10.1038/ncomms735625754609
   PubMed Web of Science ®Google Scholar
• BennionL, GrundyS. Effects of diabetes mellitus on cholesterol metabolism in man. N Engl J Med. 1977;296(24):1365–1371. doi:10.1056/NEJM197706162962401870827
   PubMed Web of Science ®Google Scholar
• AltmannS, DavisH, ZhuL, et al. Niemann-pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science. 2004;303:1201–1204. doi:10.1126/science.109313114976318
   PubMed Web of Science ®Google Scholar
• ChiangJY. Bile acid metabolism and signaling. Compr Physiol. 2013;3:1191–1212. doi:10.1002/cphy.c12002323897684
   PubMed Web of Science ®Google Scholar
• BassoF, FreemanLA, KoC, et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J Lipid Res. 2007;48(1):114–126. doi:10.1194/jlr.M600353-JLR20017060690
   PubMed Web of Science ®Google Scholar
• TontonozP, MangelsdorfDJ. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol. 2003;17(6):985–993. doi:10.1210/me.2003-006112690094
   PubMedGoogle Scholar
• TeupserD, KretzschmarD, TennertC, et al. Effect of macrophage overexpression of murine liver X receptor-alpha (LXR-alpha) on atherosclerosis in LDL-receptor deficient mice. Arterioscler Thromb Vasc Biol. 2008;28:2009–2015. doi:10.1161/ATVBAHA.108.17525718787185
   PubMed Web of Science ®Google Scholar
• BujakAL, CraneJD, LallyJS, et al. AMPK activation of muscle autophagy prevents fasting-induced hypoglycemia and myopathy during aging. Cell Metab. 2015;21(6):883–890. doi:10.1016/j.cmet.2015.05.01626039451
   PubMed Web of Science ®Google Scholar
• CarlingD. AMPK signalling in health and disease. Curr Opin Cell Biol. 2017;45:31–37. doi:10.1016/j.ceb.2017.01.00528232179
   PubMed Web of Science ®Google Scholar
• FullertonMD, FordRJ, McGregorCP, et al. Salicylate improves macrophage cholesterol homeostasis via activation of Ampk. J Lipid Res. 2015;56(5):1025–1033. doi:10.1194/jlr.M05887525773887
   PubMed Web of Science ®Google Scholar
• LiCH, GongD, ChenLY, et al. Puerarin promotes ABCA1-mediated cholesterol efflux and decreases cellular lipid accumulation in THP-1 macrophages. Eur J Pharmacol. 2017;811:74–86. doi:10.1016/j.ejphar.2017.05.05528576406
   PubMed Web of Science ®Google Scholar
• KemmererM, WittigI, RichterF, et al. AMPK activates LXRα and ABCA1 expression in human macrophages. Int J Biochem Cell Biol. 2016;78:1–9. doi:10.1016/j.biocel.2016.06.01427343431
   PubMed Web of Science ®Google Scholar
• MoluskyMM, HsiehJ, LeeSX, et al. Metformin and AMP kinase activation increase expression of the sterol transporters ABCG5/8 (ATP-binding cassette transporter G5/G8) with potential antiatherogenic consequences. Arterioscler Thromb Vasc Biol. 2018;38(7):1493–1503. doi:10.1161/ATVBAHA.118.31121229853564
   PubMed Web of Science ®Google Scholar
• JiW, ZhaoM, WangM, et al. Effects of canagliflozin on weight loss in high-fat diet-induced obese mice. PLoS One. 2017;12(6):e0179960. doi:10.1371/journal.pone.017996028665967
   PubMed Web of Science ®Google Scholar
• StenlofK, CefaluWT, KimK-A, et al. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study. Curr Med Res Opin. 2014;30(2):163–175. doi:10.1185/03007995.2013.85006624073995
   PubMed Web of Science ®Google Scholar
• StenlofK, CefaluWT, KimK-A, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15(4):372–382. doi:10.1111/dom.1205423279307
   PubMed Web of Science ®Google Scholar
• MahaffeyK, NealB, PerkovicV, et al. Canagliflozin for primary and secondary prevention of cardiovascular events: results from the CANVAS program (Canagliflozin Cardiovascular Assessment Study). Circulation. 2018;137(4):323–334. doi:10.1161/CIRCULATIONAHA.117.03203829133604
   PubMed Web of Science ®Google Scholar
• XuC, WangW, ZhongJ, et al. Canagliflozin exerts anti-inflammatory effects by inhibiting intracellular glucose metabolism and promoting autophagy in immune cells. Biochem Pharmacol. 2018;152:45–59. doi:10.1016/j.bcp.2018.03.01329551587
   PubMed Web of Science ®Google Scholar
• KimSR, LeeSG, KimSH, et al. SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11:2127. doi:10.1038/s41467-020-15983-632358544
   PubMed Web of Science ®Google Scholar
• DevineniD, PolidoriD. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 Inhibitor. Clin Pharmacokinet. 2015;54:1027–1041. doi:10.1007/s40262-015-0285-z26041408
   PubMed Web of Science ®Google Scholar
• FrambachS, de HaasR, SmeitinkJAM, et al. Brothers in arms: ABCA1- and ABCG1-mediated cholesterol efflux as promising targets in cardiovascular disease treatment. Pharmacol Rev. 2020;72:152–190. doi:10.1124/pr.119.01789731831519
   PubMed Web of Science ®Google Scholar
• WangB, TontonozP. Liver X receptors in lipid signalling and membrane homeostasis. Nat Rev Endocrinol. 2018;14(8):452–463. doi:10.1038/s41574-018-0037-x29904174
   PubMed Web of Science ®Google Scholar
• HelgadottirA, ThorleifssonG, AlexanderssonKF, et al. Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease. Eur Heart J. 2020;41(28):2618–2628. doi:10.1093/eurheartj/ehaa53132702746
   PubMed Web of Science ®Google Scholar
• CastanoD, RattanasopaC, Monteiro-CardosoVF, et al. Lipid efflux mechanisms, relation to disease and potential therapeutic aspects. Adv Drug Deliv Rev. 2020;159:54–93.32423566
   PubMed Web of Science ®Google Scholar
• HeY, RonseinGE, TangC, et al. Diabetes impairs cellular cholesterol efflux from ABCA1 to small HDL particles. Circ Res. 2020;127(9):1198–1210. doi:10.1161/CIRCRESAHA.120.31717832819213
   PubMed Web of Science ®Google Scholar
• GoedekeL, RotllanN, Canfrán-DuqueA, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels. Nat Med. 2015;21(11):1280–1289. doi:10.1038/nm.394926437365
   PubMed Web of Science ®Google Scholar
• HawleySA, FordRJ, SmithBK, et al. The Na+/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes. 2016;65(9):2784–2794. doi:10.2337/db16-005827381369
   PubMed Web of Science ®Google Scholar
• YangX, LiuQ, LiY, et al. The diabetes medication canagliflozin promotes mitochondrial remodelling of adipocyte via the AMPK-Sirt1-Pgc-1α signalling pathway. Adipocyte. 2020;9(1):484–494. doi:10.1080/21623945.2020.180785032835596
   PubMed Web of Science ®Google Scholar
• Nasiri-AnsariΝ, DimitriadisGK, AgrogiannisG, et al. Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice. Cardiovasc Diabetol. 2018;17(1):106. doi:10.1186/s12933-018-0749-130049285
   PubMed Web of Science ®Google Scholar
• YuT, SungeloMJ, GoldbergIJ, et al. Streptozotocin-treated high fat fed mice: a new type 2 diabetes model used to Study Canagliflozin-Induced Alterations in Lipids and Lipoproteins. Horm Metab Res. 2017;49:400–406. doi:10.1055/s-0042-11093428395380
   PubMed Web of Science ®Google Scholar
• BasuD, HugginsLA, ScerboD, et al. Mechanism of increased LDL (Low-Density Lipoprotein) and decreased triglycerides with SGLT2 (Sodium-Glucose Cotransporter 2) inhibition. Arterioscler Thromb Vasc Biol. 2018;38:2207–2216. doi:10.1161/ATVBAHA.118.31133930354257
   PubMed Web of Science ®Google Scholar
• DayEA, FordRJ, LuJH, et al. The SGLT2 inhibitor canagliflozin suppresses lipid synthesis and interleukin-1 beta in ApoE deficient mice. Biochem J. 2020;477:2347–2361. doi:10.1042/BCJ2020027832510137
   PubMed Web of Science ®Google Scholar
• WangHH, LiT, PortincasaP, et al. New insights into the role of Lith genes in the formation of cholesterol-supersaturated bile. Liver Res. 2017;1(1):42–53. doi:10.1016/j.livres.2017.05.005
   Google Scholar
• WilundKR, YuL, XuF, et al. High-level expression of ABCG5 and ABCG8 attenuates diet-induced hypercholesterolemia and atherosclerosis in Ldlr−− mice. J Lipid Res. 2004;45(8):1429–1436. doi:10.1194/jlr.M400167-JLR20015175362
   PubMed Web of Science ®Google Scholar
• GonzálezA, HallMN, LinS-C, et al. AMPK and TOR: the Yin and Yang of cellular nutrient sensing and growth control. Cell Metab. 2020;31:472–492.32130880
   PubMed Web of Science ®Google Scholar
• LienF, BerthierA, BouchaertE, et al. Metformin interferes with bile acid homeostasis through AMPK-FXR crosstalk. J Clin Invest. 2014;124(3):1037–1051. doi:10.1172/JCI6881524531544
   PubMed Web of Science ®Google Scholar
• LefterovI, BookoutA, WangZ, et al. Expression profiling in APP23 mouse brain: inhibition of Aβ amyloidosis and inflammation in response to LXR agonist treatment. Mol Neurodegener. 2007;2(1):20. doi:10.1186/1750-1326-2-2017953774
   PubMed Web of Science ®Google Scholar
• ManciniSJ, BoydD, KatwanOJ, et al. Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms. Sci Rep. 2018;8(1):5276. doi:10.1038/s41598-018-23420-429588466
   PubMed Web of Science ®Google Scholar
• QiangL, SampleA, SheaCR, et al. Autophagy gene ATG7 regulates ultraviolet radiation-induced inflammation and skin tumorigenesis. Autophagy. 2017;13(12):2086–2103. doi:10.1080/15548627.2017.138075728933598
   PubMed Web of Science ®Google Scholar
• MaA, WangJ, YangL, et al. AMPK activation enhances the anti-atherogenic effects of high density lipoproteins in apoE−/− mice. J Lipid Res. 2017;58(8):1536–1547. doi:10.1194/jlr.M07327028611100
   PubMed Web of Science ®Google Scholar
• CedoL, MetsoJ, SantosD, et al. LDL receptor regulates the reverse transport of macrophage-derived unesterified cholesterol via concerted action of the HDL-LDL axis: insight from mouse models. Circ Res. 2020;127:778–792. doi:10.1161/CIRCRESAHA.119.31642432495699
   PubMed Web of Science ®Google Scholar